Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

Overview of attention for article published in Cancer Research, July 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 16,218)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 32 news outlets

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 9 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 32 news stories from 32 outlets.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

ProfitQuotes.com, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WCAX, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KCBD, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 34 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

NBC12, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 33 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KLTV, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WFLX Fox 29, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 32 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WWSB, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 31 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Fox 8 WVUE, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WAFB 9, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WTVM, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WALB, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KEYC News 12, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 30 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WECT News 6, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 30 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WMBF News, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 30 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Benzinga, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

PR Newswire, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WILX 10, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 27 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WSAW-TV, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 27 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KAIT-TV, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 28 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Hawaii News Now, 03 Nov 2021

Published: Nov. 3, 2021 at 2:00 AM HST|Updated: 29 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Knoe News 8, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 29 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WBTV, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 26 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

14 News, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 26 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Fox 19, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KSLA News 12, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Wave 3 News, 03 Nov 2021

Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 25 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WDAM - TV, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 25 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KPLC 7 News, 03 Nov 2021

Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 24 minutes ago CAMBRIDGE, Mass., Nov.

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Yahoo! Finance USA, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WFMZ-TV 69, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

South Carolina News Now, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Biospace, 03 Nov 2021

CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ --Sumitomo Dainippon Pharma Co., Ltd.

American Association for Cancer Research

Article Metrics

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

About this Attention Score

Mentioned by

Citations

Readers on

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

ProfitQuotes.com, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WCAX, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KCBD, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

NBC12, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KLTV, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WFLX Fox 29, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WWSB, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Fox 8 WVUE, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WAFB 9, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WTVM, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WALB, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KEYC News 12, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WECT News 6, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WMBF News, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Benzinga, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

PR Newswire, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WILX 10, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WSAW-TV, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KAIT-TV, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Hawaii News Now, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Knoe News 8, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WBTV, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

14 News, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Fox 19, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KSLA News 12, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Wave 3 News, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WDAM - TV, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

KPLC 7 News, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Yahoo! Finance USA, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

WFMZ-TV 69, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

South Carolina News Now, 03 Nov 2021

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma

Biospace, 03 Nov 2021